Merck KGaA (XTRA:MRK), Why Is It Getting Attention Today?

Merck KGaA (XTRA:MRK) just entered new clinical trial collaboration and supply agreements around cetuximab with Adlai Nortye and Eli Lilly, tying the pharmaceutical group more closely to early stage oncology research.

Investors have leaned into Merck KGaA over 2026, with the share price at €144.30 and a 30-day share price return of 11.13% helping to drive an 18.96% year to date gain. The 1-year total shareholder return of 31.19% contrasts with a 23.00% decline over five years, hinting at momentum rebuilding as oncology partnerships like the new cetuximab collaboration refocus attention on the long term pipeline and perceived risk profile.

Scan other oncology-focused opportunities moving on fresh trial news with our curated list of 127 healthcare AI stocks, which highlights companies pairing drug development with AI-driven research platforms.

The rebound in Merck KGaA after years of weaker long term returns could reflect investors reassessing the business rather than simply responding to oncology headlines. The valuation now needs to be weighed against that change in sentiment.

Most Popular Merck KGaA Narrative: 6% Undervalued

On the widely followed narrative, Merck KGaA screens as modestly undervalued, with a fair value of €154.21 against the latest close at €144.30, and that gap rests on detailed assumptions about AI linked semiconductors, Life Science workflows and rare disease drugs.

The strong AI related demand for advanced node semiconductor materials and metrology, with Semiconductor Solutions organic growth of 17% in Q2 2026 and customers expected to remain capacity constrained into at least 2027, can support higher Electronics revenue and EBITDA pre over the next few years. The in region for region capacity build out across Life Science and Electronics, including the semiconductor megasite in Taiwan, the US semiconductor R&D center and new bioprocessing and testing facilities, can support resilient regional revenue growth and protect segment EBITDA pre margins through a more reliable supply chain.

See why 60 investors see Merck KGaA as 6% undervalued.

Result: Fair Value of €154.21 (UNDERVALUED)

Still, any disappointment in integrating Bio-Techne or weaker Healthcare earnings as Mavenclad winds down could quickly change the Merck KGaA undervaluation story.

Find out about the key risks to this Merck KGaA narrative.

Next Steps

That optimistic tilt around Merck KGaA is only part of the story, so move fast and pressure test the numbers for yourself. To see what has investors excited, review the 3 key rewards

Looking for more investment ideas beyond Merck KGaA?

Do not stop at Merck KGaA if you want a fuller picture of where your next opportunity might come from, especially with sector stories moving quickly.

• Target steady cash generators by screening for companies with strong payouts and stability through the 216 dividend fortresses.
• Spot potential bargains early by scanning a curated set of quality businesses trading below their estimated worth using the 191 high quality undervalued stocks.
• Zero in on resilience by filtering for companies that pair durable fundamentals with lower overall risk through the 234 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com